Financial Services
Make smarter pharma and biotech investment decisions with Evaluate
Evaluate gives investment banks, private equity firms, venture capital investors and hedge funds a clearer view of the companies, assets, markets and forecasts shaping pharma and biotech investment decisions.
Use trusted data, forecasts and expert insight to assess opportunities, pressure-test assumptions and make confident decisions across the healthcare landscape.
Built for financial services
See the market behind every investment decision
Pharma and biotech investment decisions depend on more than headline data. Teams need to understand asset potential, market size, forecast confidence, pipeline risk, competitive pressure, catalyst timing and the assumptions behind future value.
Evaluate brings these signals together, helping investors, analysts, dealmakers and advisors assess opportunities, validate market assumptions and build stronger investment cases across pharma and biotech.
companies covered
pharma and biotech products tracked
consensus forecasts
forecasted assets
See how Evaluate supports your investment strategy
For investment banks
Build stronger valuation narratives for biotech M&A, IPOs, capital raising and strategic advisory. Use Evaluate to assess market potential, benchmark forecasts, monitor catalysts and support client recommendations with evidence-backed insight.
Explore investment banking workflows >
For venture capital
Screen emerging biotech opportunities, assess asset potential and monitor the signals that could shape portfolio growth. Evaluate supports early-stage diligence, market sizing, portfolio strategy and exit planning.
Explore venture capital workflows >
For private equity
Assess pharma and biotech targets, pressure-test commercial assumptions and evaluate the market case behind potential investments. Evaluate supports commercial diligence, investment committee materials and portfolio value creation.
Explore private equity workflows >
For hedge funds
Track catalysts, forecast revisions, regulatory events and competitive changes that could affect pharma and biotech company valuations. Evaluate to supports investment research, position monitoring and event-driven analysis.
Explore hedge fund workflows >
Explore our products
Our experts will help you identify the tools and insights that support your strategic, commercial, or investment priorities.
Find the best-fit solution for your goals
Not sure which solutions are right for you? Get in touch with our team, and we’ll talk through your needs.
Latest Resources
Build stronger pharma and biotech investment strategies with Evaluate
See how Evaluate helps venture capital teams source opportunities, assess market potential, monitor risks and support portfolio companies with trusted biopharma intelligence.
Frequently Asked Questions
How does Evaluate support financial services professionals?
Evaluate helps financial services professionals assess pharma and biotech opportunities with trusted forecasts, company intelligence, asset-level data, market context and expert insight. Teams use Evaluate to understand market potential, pressure-test assumptions, monitor competitive movement and build stronger investment cases.
Which financial services audiences use Evaluate?
Evaluate supports investment banks, private equity firms, venture capital investors and hedge funds working across pharma, biotech and healthcare markets. Each audience uses Evaluate differently, from valuation support and commercial diligence to market mapping, portfolio monitoring and catalyst analysis.
How can investment banks use Evaluate?
Investment banks use Evaluate to support pharma and biotech M&A, IPO preparation, capital raising and strategic advisory work. Evaluate helps teams assess market opportunity, benchmark forecasts, analyze company and asset potential, and support client recommendations with evidence-backed insight.
How can private equity firms use Evaluate?
Private equity firms use Evaluate to assess pharma and biotech targets, pressure-test commercial assumptions and understand the market case behind potential investments. Evaluate can support commercial due diligence, investment committee preparation, market sizing and portfolio value creation.
How can venture capital investors use Evaluate?
Venture capital investors use Evaluate to identify and assess emerging biotech opportunities, understand asset potential, monitor market signals and support portfolio strategy. Evaluate can help with early-stage diligence, market mapping, competitive assessment and exit planning.
How can hedge funds use Evaluate?
Hedge funds use Evaluate to monitor catalysts, forecast revisions, regulatory events, competitive changes and other signals that may affect biotech company valuations. Evaluate supports investment research, position monitoring and event-driven analysis across pharma and biotech.
